ArticlePloS one2025
Effect of intestinal microbiota on growth rate of Babylonia areolata.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To analyze the differences in the intestinal microbiota structure of different growth rates of Babylonia areolata, the sequencing of the V3-V4 regions of 16S rDNA from intestinal samples was performed. Evaluation of the richness of microbiota of the samples by calculating Shannon index, Simpson index and Chao1 index showed that the community diversity and richness of the intestinal microbiota of B. areolata changed for different growth rates. There are differences in the diversity of the intestinal microbiota in the fast growth rate (FG) and slow growth rate (SG) groups. A total of 315,294 reads of 16S rDNA were obtained from 6 samples, and 17 phyla were identified by RDP classifier. After data standardization, the dominant phyla from FG and SG were Firmicutes, Proteobacteria, and Bacteroidetes, 50.23%, 39.31% and 8.39% in the FG group, and 79.97%, 12.05% and 6.21% in the SG group, respectively. The distribution of the intestinal microbiota in the FG group is relatively uniform, but the Mycoplasma in the SG group is the dominant genus accounting for about 63%. At the genus level, compared to the SG group, the FG group exhibited a significant increase in the abundance of Exiguobacterium, Vibrio, and Escherichia-Shigella, while the abundance of Mycoplasma, Citrobacter, and Phascolaretobacterum was significantly reduced. These findings provide novel information for studying the differences in the intestinal microbiota of B. areolata with different growth rates, and a foundation for future research on intestinal bacterial factors that may affect the growth and cultivation of B. areolata.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.